Insider Selling: Halozyme Therapeutics, Inc. (NASDAQ:HALO) SVP Sells $98,901.16 in Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) SVP Michael J. Labarre sold 1,697 shares of Halozyme Therapeutics stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $58.28, for a total value of $98,901.16. Following the completion of the transaction, the senior vice president now owns 173,756 shares of the company’s stock, valued at approximately $10,126,499.68. This trade represents a 0.97 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Halozyme Therapeutics Trading Up 2.5 %

Shares of HALO stock opened at $59.15 on Friday. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14. The business has a 50-day moving average price of $54.53 and a two-hundred day moving average price of $54.75. Halozyme Therapeutics, Inc. has a 12-month low of $37.73 and a 12-month high of $65.53. The firm has a market cap of $7.28 billion, a P/E ratio of 17.24, a price-to-earnings-growth ratio of 0.42 and a beta of 1.25.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.17 by $0.02. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The firm had revenue of $298.01 million during the quarter, compared to analyst estimates of $285.74 million. Equities analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Institutional Investors Weigh In On Halozyme Therapeutics

Several hedge funds have recently added to or reduced their stakes in HALO. Heck Capital Advisors LLC bought a new stake in shares of Halozyme Therapeutics in the 4th quarter valued at about $29,000. CBIZ Investment Advisory Services LLC bought a new stake in shares of Halozyme Therapeutics in the 4th quarter valued at about $29,000. Smartleaf Asset Management LLC lifted its stake in shares of Halozyme Therapeutics by 29.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company’s stock valued at $42,000 after acquiring an additional 197 shares during the last quarter. Venturi Wealth Management LLC bought a new stake in shares of Halozyme Therapeutics in the 4th quarter valued at about $69,000. Finally, Parkside Financial Bank & Trust lifted its stake in shares of Halozyme Therapeutics by 21.8% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company’s stock valued at $86,000 after acquiring an additional 322 shares during the last quarter. Institutional investors own 97.79% of the company’s stock.

Wall Street Analyst Weigh In

HALO has been the subject of several recent research reports. Wells Fargo & Company reduced their price target on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. Piper Sandler boosted their target price on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research report on Friday, January 10th. Benchmark restated a “buy” rating and set a $75.00 target price on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. Finally, HC Wainwright boosted their target price on Halozyme Therapeutics from $70.00 to $72.00 and gave the stock a “buy” rating in a research report on Wednesday, February 19th. Four analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $62.78.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.